Fulgent Genetics Stock

Fulgent Genetics ROCE

The Return on Capital Employed (ROCE) of Fulgent Genetics (FLGT) as of Aug 12, 2026 is -8.23 %. In the previous year, Return on Capital Employed (ROCE) was -6.55 % — a change of 25.74% (lower).

ROCE

-8.23 %

YoY

25.74%

Last updated:

In 2026, Fulgent Genetics's return on capital employed (ROCE) was -8.23 %, a 25.74% increase from the -6.55 % ROCE in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Fulgent Genetics Stock analysis

What does Fulgent Genetics do? Fulgent Genetics Inc. is a US company founded in 2011 by Jianxing (Justin) Liu and Ming Hsieh. The company has undergone remarkable development and is now active in the field of genomics and genetics. Fulgent Genetics' business model is based on the development and distribution of solutions for the diagnosis of genetic diseases. The company offers a variety of products and services that enable doctors, clinics, and laboratories to make effective diagnoses based on genetics. One of Fulgent Genetics' main divisions is the Clinical Diagnostics department, which offers a wide range of diagnostic products that allow for both molecular diagnoses and the creation of clinical profiles for patients. This enables doctors and clinics to quickly and accurately detect and treat specific diseases. Another important division of Fulgent Genetics is the Research department, which focuses on the discovery and development of new technologies and testing procedures. These technologies and procedures are of great interest to the scientific community and are used in research or clinical studies. Fulgent Genetics also offers a Pharmacogenomics department, which is a growing segment in the personalized medicine market. The goal here is to tailor medications to the patient's genetic makeup. Fulgent Genetics' technology allows for the analysis of a patient's current genetic makeup and recommends medications based on that. Another important area of Fulgent Genetics is the direct-to-consumer sales of tests. This is particularly significant in the field of ancestry and genealogy research. Fulgent Genetics offers a variety of tests in this area and has already achieved great success. Overall, Fulgent Genetics offers a wide range of products and services mainly focused on the diagnosis of genetic diseases. However, the company also goes beyond that and provides solutions for a wide range of customers and applications. Fulgent Genetics is based in the US and has experienced rapid growth since its founding. The company's success is also reflected in the many awards it has received. It has been recognized multiple times and has established a reputation as one of the leading biotechnology companies in the world. Fulgent Genetics is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Fulgent Genetics's Return on Capital Employed (ROCE)

Fulgent Genetics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Fulgent Genetics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Fulgent Genetics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Fulgent Genetics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Fulgent Genetics stock

Return on Capital Employed (ROCE) of Fulgent Genetics is -8.23 % in 2026.

Return on Capital Employed (ROCE) of Fulgent Genetics changed from -6.55 % to -8.23 %, representing a 25.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Fulgent Genetics since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Fulgent Genetics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Fulgent Genetics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Fulgent Genetics